Prognostic biomarker tumor-infiltrating lymphocytes failed to serve as a predictive biomarker for postoperative radiotherapy in completely resected pN2 non-small cell lung cancer: a retrospective analysis
Jiaran Li, Li Li, Jingjing Wang, Ning Liu, Haixin Liu, Fuhao Xu, Mengke Li, Shuanghu Yuan

TL;DR
Tumor-infiltrating lymphocytes (TILs) are linked to better survival in lung cancer patients but do not predict the effectiveness of post-surgery radiotherapy.
Contribution
This study shows TILs are a prognostic marker but not a predictive one for radiotherapy outcomes in stage III NSCLC.
Findings
High TILs levels correlate with improved disease-free and overall survival in completely resected pN2 NSCLC patients.
TILs levels are higher in patients who received postoperative radiotherapy compared to those who did not.
No significant survival differences were found between treatment groups based on TILs infiltration levels.
Abstract
Evidence suggests that radiotherapy is a potent immunomodulator in non-small cell lung cancer (NSCLC). Conversely, it has rarely been demonstrated if immune infiltration can influence radiotherapy efficacy. Herein, we explored the effect of tumor-infiltrating lymphocytes (TILs) on the response to postoperative radiotherapy (PORT) in completely resected stage III-pN2 NSCLC. This retrospective study included 244 patients with pathologically confirmed stage III-N2 NSCLC who underwent complete resection at our institution between 2014 and 2020. TILs were assessed with permanent full-face hematoxylin and eosin (H&E) sections and the evaluation of TILs was based on a published guideline. Patients were stratified into the TILlow or TILhigh group with a cutoff value of 50%. Kaplan-Meier method and Log‐rank test were utilized to assess disease-free survival (DFS) and overall survival (OS).…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer Immunotherapy and Biomarkers · Inflammatory Biomarkers in Disease Prognosis · Lung Cancer Diagnosis and Treatment
